Member Info for crumbs

I'm not expecting more dilution just yet but am sceptical of- funded till 2021... if modi1 trial begins with no partner H1 2020 I'd expect that to be a raising trigger and Vulpes may very well be signed up to that possibility already ... obviously things are happening with shuffles on the board and science constant progress and new patents...we can but hope for the outcome to be our first money up front big bio/pharma deal/s ... so far not happened! lol ... of course can appear at any moment though... the mystery partner on MaBs is investigating them to a 'one year plan' now of course that does not mean they will only make a move in after a year as will depend in what their scientists are seeing and reporting back etc.. but we should err on side of will be a year before they at least make a move ... so next Sept.... BioNtech and TCR could be sooner - H1 2020... and of course modi1 partner could come anytime... as the progress towards getting that product into the clinic continues apace ... and we see Lindy is going to be presenting about it at some rather big science conferences.

C7 I might be wrong but very much doubt the new big buys are Vulpes as surely they would buy in a placing so as to give scancell more funds?..... If we find out who or not I'm not too sure as you say they need a rather large amount to trigger an RNS but someone/s have wanted a very large amount of shares and gotten them at a price I doubt we would have for that amount!

Certainly interesting .... and does look like someone seriously getting in.... more news to come? I dunno... Always have hoped modi1 would go into trial with a big partner paying... still hoping on that one...

Antisoma was indeed a disaster but not because of Ursula...as that book reveals......be thankful for this company having a team science.....we need deals she is well thought of in the industry and well connected

haha but it does not cast her in a bad light to be fair... that company was to my mind much more like a VAL than scancell... its failed tech all bought in and not understood and then a huge gamble on success on murky early data that managed to bring in Novartis to foot the bill...oh for a Novartis here!

But not a massive sp rise... C7 report :) what's going on?.. some more news on its way?

It's actually a good read.. I've gotten into it lol..... Anyone wanting to know about risk/reward in this sector should have a read....

Think rats will appreciate this literary work... cant cut and paste but the link is here

https://books.google.co.uk/books?id=LzcXBgAAQBAJ&pg=PT19&lpg=PT19&dq=ursula+ney&source=bl&ots=qCb7-BEUhy&sig=ACfU3U3yjtmADDmSrwcYJWJXevNUTyQt-w&hl=en&sa=X&ved=2ahUKEwj4-YCv1LLlAhVXiVwKHebTDxI4FBDoATAAegQICBAB#v=onepage&q=ursula%20ney&f=false

Goodness knows what the scancell saga would be like......

Yes to all that... certainly, Ursula seems the type we want-able and well connected, though her Antisoma experience is not one we want to be repeating here ... ouch!
I'm all for a new Diggle influence period of scancell seeing as the non-team science contingent so far have brought us nothing beyond an ever-shrinking mcap with its attached sp..... Be good if ole Evans gives a view over on the other side :)

' She was listed in the 50 Movers and Shakers in Biobusiness 2017.'

Well we could do with a bit of that lol

Boom do you reckon this might be a Diggle influence coming in, changing of the old guard?..... I welcome it if so :)

'Dr. Ursula M. Ney has more than thirty years’ experience in the pharmaceutical and biotech industry, with twenty years in leadership roles in the Biotech sector. She was Director of Development and on the Board of Celltech plc, and later COO and Executive director of another UK public company Antisoma plc. More recently she was CEO of the private company Genkyotex SA and is currently a Non-Executive Director on the board of Discuva, a Cambridge, UK based start up. In her roles at Celltech and Antisoma she had responsibilities for operations in the USA and Europe and has broad experience of drug development across a range of therapeutic areas and products in both territories including in partnership with a number of major US based pharma companies. Her responsibilities have also included licensing and M&A and she has considerable experience of corporate and commercial strategies in the biotech sector. Her early career was spent at Sandoz (Switzerland) then Roche (UK) after obtaining a PhD in pharmacology from the Royal Free Hospital Medical School, London and later a MBA'

Make it a strong one lol

Indeed it is all about translating science into survival ... however not all science is equal or all scientists .... you cannot help be impressed with scancells science and scientists ... the amount of work that is and has gone into moditope being an example I am heartened that not only has the moditope mechanism been shown to exist in humans both healthy and cancer sufferers using donated blood... but now scancell are looking into how tumors may protect themselves from or halt that mechanism from translating into survival and how that can be overcome... those things to my mind is what makes the difference and is what makes scancell a science powerhouse if only a biotech market minnow... anyways as for translating that into sp ... it wont be the data IMHO it will be the deal/s we never got any sp benefit from SCIB1 success.... sure modi1 ought to be different but I would not trust AIM to value amazing incoming data they would need someone else to do it for them.... the deal/s

To watch BioNtechs NASDAQ experience ... their sp began to tank which is often the case post listing however it seems to now be gaining momentum so seems there is an appetite for their shares... their current mcap $3.7 billion ... not bad eh... Well, they are a company that will have positive newsflow.... plenty of trial data to be coming in (5 trials ongoing I think) ... Will they manage to keep the Lilly TCR deal alive and continue getting income from it is yet to be announced and I'd say is not looking hopeful seeing as no payment from Lilly to them this year up to listing as they are evaluating what their collab has produced so far.... could BioNTech let them in on scancell TCRs (presuming those candidates are finalised).... possibly... anyways at least our current 'research' partner is having a better sp time of it than us :)

I think the science ones are very important... this one in Boston, for instance, should get LD some more good exposure in the exciting emerging area of neoantigen science with some impressive names there.... including like I say our moditope collaborators ISA and polypeptide group.... let em all know modi1 trial is coming!... We hope :)
But I know what you are getting at lol....

Next year at this one too...

'Stress-Induced Post-Translational Modifications (siPTMs) as Targets for Cancer Vaccines

Lindy Durrant, PhD, Professor of Cancer Immunotherapy, University of Nottingham'

https://www.immuno-oncologyeurope.com/preclinical-immuno-oncology

the 'in mice and humans' is notable lol... but an interesting and no doubts not too cheap conference to be attending

Day 2

'14.00 Citrullination- A Widely Expressed, Novel, Stress Induced Post-Translational Modification that is a Potent Target for Cancer Vaccines

• There is a repertoire of cytotoxic CD4 T cells in mice and humans that recognizes citrullinated vimentin and enolase
• Inflammation and stress induces high levels of autophagy and MHC-II presentation of citrullinated epitopes on tumors
• Citrullinated peptides linked to the TLR1/2 adjuvant, Amplivant, demonstrate potent anti-tumor immunity with no associated toxicity and will shorty enter the clinic

Lindy Durrant, Professor of Cancer Immunotherapy, University of Nottingham'

Notice ISA are there as are polypeptide group... and ooh Genentech... how we can but hope lol

Next month... who is that I see among the speakers!
https://neo-antigen.com/speakers/